

Supplementary Table 13. Concurrent driver mutations according to oncogenic / likely oncogenic *MET* TKD mutations detected in cohort #2.

MET Kinase Domain Mutation	No concurrent driver mutations present (N=78)	Concurrent <i>KRAS</i> mutation (N=33)	Concurrent <i>EGFR</i> mutation (N=11)	Concurrent <i>ROS1</i> Fusion (N=3)	Concurrent <i>ALK</i> Fusion (N=2)	Concurrent <i>BRAF</i> mutation (N=2)	Concurrent <i>MET</i> amplification (N=13)
H1094X	25 (19.0%)	14 (10.5%)	6 (4.7%)	0	0	1 (0.8%)	3 (2.3%)
L1195X	18 (14.0%)	5 (3.9%)	1 (0.8%)	0	0	1 (0.8%)	3 (2.3%)
D1228X	9 (7%)	4 (3.1%)	2 (1.5%)	2 (1.5%)	2 (1.5%)	0	5 (3.8%)
Y1230X	9 (7%)	2 (1.5%)	0	1 (0.8%)	0	0	0
H1106X	5 (3.9%)	2 (1.5%)	0	0	0	0	1 (0.8%)
M1250X	3 (2.4%)	3 (2.3%)	0	0	0	0	0
F1080X	0	1 (0.8%)	2 (1.5%)	0	0	0	0
V1092X	3 (2.4%)	1 (0.8%)	0	0	0	0	1 (0.8%)
V1220X	3 (2.4%)	0	0	0	0	0	0
F1200X	1 (0.8%)	1 (0.8%)	0	0	0	0	0
N1100T	1 (0.8%)	0	0	0	0	0	0
Y1235H	1 (0.8%)	0	0	0	0	0	0

*Percentages are calculated considering the total number of cases (N=129) as denominator.